2025 / 05

Next Paper
DOI: 10.24075/brsmu.2025.047
Copyright: © 2025 by the authors. Licensee: Pirogov University.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).

ORIGINAL RESEARCH

Panel of IFN-I-induced genes in systemic scleroderma: a stratification biomarker potential

Shagina IA1,2,5, Turchaninova MA2,5, Golovina OA3, Bufeeva LS2,5, Zhurina TI3, Saifullin RF1,4, Myshkin MYu2,5, Mutovina ZYu3, Britanova OV2,5
About authors

1 Pirogov Russian National Research Medical University, Moscow, Russia

2 MyLaboratory LLC, Moscow, Russia

3 Moscow City Research Center Hospital No. 52, Moscow, Russia

4 Federal Scientific and Clinical Center of Resuscitation and Rehabilitation, Moscow, Russia

5 Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry Russian Academy of Sciences, Moscow, Russia

Correspondence should be addressed: Olga V. Britanova
Miklukho-Maklaya, 16/10, Moscow, 117997, Russia; moc.liamg@natirblo; Zinaida Yu. Mutovina — Pekhotnaya, 3, Moscow, 123182, Russia, ur.liam@anivotumz

About paper

Funding: the study was supported by the grant from the Moscow Government (R&D project No. 1603-47/23 dated 08.06.2023), sponsored by the Moscow Center for Innovative Technologies in Healthcare.

Author contribution: Mutovina ZYu — concept; Zhurina TI, Saifullin RF — acquisition of rheumatology and medicine data; literature review; Myshkin MYu — data analysis; Bufeeva LS — sample collection, RNA extraction; Shagina IA — RT-qPCR optimization and procedure, primary data analysis, manuscript writing, literature review; Turchaninova MA, Golovina OA, Britanova OV — manuscript writing, literature review.

Compliance with ethical standards: the study was conducted in accordance with the Declaration of Helsinki. The informed consent for biomaterial collection and testing during inpatient assessment settings was obtained from all patients.

Received: 2025-09-06 Accepted: 2025-10-08 Published online: 2025-10-21
|
  1. Elhai M, Meune C, Avouac J, Kahan A, Allanore Y. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford). 2012; 51 (6): 1017–26. DOI: 10.1093/rheumatology/ker269. PMID: 21900368.
  2. Rubio-Rivas M, Royo C, Simeón CP, Corbella X, Fonollosa V. Mortality and survival in systemic sclerosis: systematic review and meta-analysis. Semin Arthritis Rheum. 2014; 44 (2): 208–19. DOI: 10.1016/j.semarthrit.2014.05.010.
  3. Nikpour M, Baron M. Mortality in systemic sclerosis: lessons learned from population-based and observational cohort studies. Curr Opin Rheumatol. 2014; 26 (2): 131–7. DOI: 10.1097/BOR.0000000000000027.
  4. Elhai M, Meune C, Boubaya M, et al. EUSTAR group. Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis. 2017; 76 (11): 1897–905. DOI: 10.1136/annrheumdis-2017-211448.
  5. Rosa JE, Soriano ER, Narvaez-Ponce L, et al. Incidence and prevalence of systemic sclerosis in a healthcare plan in Buenos Aires. J Clin Rheumatol. 2011; 17 (2): 59–63. DOI: 10.1097/RHU.0b013e31820e7e8d.
  6. Furst DE, Fernandes AW, Iorga SR, Greth W, Bancroft T. Epidemiology of systemic sclerosis in a large US managed care population. J Rheumatol. 2012; 39 (4): 784–6. DOI: 10.3899/jrheum.111106.
  7. Horimoto AMC, Matos ENN, Costa MRD, et al. Incidence and prevalence of systemic sclerosis in Campo Grande, Brazil. Rev Bras Reumatol (Engl Ed). 2017; 57 (2): 107–14. DOI: 10.1016/j.rbre.2016.09.005.
  8. Hoffmann-Vold AM, Midtvedt Ø, Molberg Ø, Garen T, Gran JT. Prevalence of systemic sclerosis in south-east Norway. Rheumatology (Oxford). 2012; 51 (9): 1600–5. DOI: 10.1093/rheumatology/kes076.
  9. Bajraktari IH, Berisha I, Berisha M, et al. Incidence, prevalence and clinical manifestations of systemic sclerosis in Dukagjini plain. Mater Sociomed. 2013; 25 (1): 14–18. DOI: 10.5455/msm.2013.25.14-18.
  10. El Adssi H, Cirstea D, Virion JM, Guillemin F, de Korwin JD. Estimating the prevalence of systemic sclerosis in Lorraine, France, by the capture-recapture method. Semin Arthritis Rheum. 2013; 42 (5): 530–38. DOI: 10.1016/j.semarthrit.2012.10.001.
  11. Meier FM, Frommer KW, Dinser R, et al. EUSTAR Co-authors. Update on the profile of the EUSTAR cohort. Ann Rheum Dis. 2012; 71 (8): 1355–60. DOI: 10.1136/annrheumdis-2011-200742.
  12. Matucci-Cerinic M, Krieg T, Guillevin L, et al. Burden of recurrent and chronic digital ulcers in systemic sclerosis: long-term results from the DUO Registry. Ann Rheum Dis. 2016; 75 (10): 1770–6. DOI: 10.1136/annrheumdis-2015-208121.
  13. Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: EUSTAR database study. Ann Rheum Dis. 2010; 69 (10): 1809–15. DOI: 10.1136/ard.2009.114264.
  14. Assassi S, Mayes MD, Arnett FC, et al. Systemic sclerosis and lupus: points in an interferon-mediated continuum. Arthritis Rheum. 2010; 62 (2): 589–98. DOI: 10.1002/art.27224.
  15. Gasparini G, Cozzani E, Parodi A. Interleukin-4 and interleukin-13 as possible therapeutic targets in systemic sclerosis. Cytokine. 2020; 125: 154799. DOI: 10.1016/j.cyto.2019.154799.
  16. Wei L, Abraham D, Ong V. The Yin and Yang of IL-17 in systemic sclerosis. Front Immunol. 2022; 13: 885609. DOI: 10.3389/fimmu.2022.885609.
  17. Skaug B, Assassi S. Type I interferon dysregulation in systemic sclerosis. Cytokine. 2020; 132: 154635. DOI: 10.1016/j.cyto.2018.12.018.
  18. Farutin V, Pradines JR, Cilfone NA, Ghavami A, Kurtagic E, Guess J, et al. Multiomic study of skin, peripheral blood, and serum: is serum proteome a reflection of disease process at the end-organ level in systemic sclerosis? Arthritis Res Ther. 2021; 23 (1): 259. DOI: 10.1186/s13075-021-02633-5.
  19. Nasonov EL. Sovremennaya koncepciya autoimmuniteta v revmatologii. Nauchno-prakticheskaya revmatologiya. 2023; 61 (4): 397–420. DOI: 10.47360/1995-4484-2023-397-420. Russian.
  20. Paradowska-Gorycka A, Wajda A, Stypinska B, et al. Endosomal TLRs and interferons expression in SLE, SSc and MCTD. Clin Exp Immunol. 2021; 204 (1): 49–63. DOI: 10.1111/cei.13566.
  21. Yin H, Distler O, Shen L, et al. Endothelial response to type I interferon contributes to vasculopathy and fibrosis and predicts progression in systemic sclerosis. Arthritis Rheumatol. 2024; 76 (1): 78–91. DOI: 10.1002/art.42662. PMID: 37488975.
  22. Tinazzi I, Mulipa P, Colato C, et al. SFRP4 expression is linked to immune-driven fibrotic conditions and correlates with skin and lung fibrosis in SSc. J Clin Med. 2021; 10 (24): 5820. DOI: 10.3390/jcm10245820.
  23. Nasonov EL, Avdeeva AS. Immunovospalitel'nye revmaticheskie zabolevaniya, svyazannye s interferonom tipa I: novye dannye. Nauchno-prakticheskaya revmatologiya. 2019; 57 (4): 452–61. Russian.
  24. Avdeeva AS, CHetina EV, CHerkasova MV, Markova GA, Artyuhov AS, Dashinimaev EB, et al. Ekspressiya interferon-stimulirovannyh genov (interferonovyj «avtograf») u pacientov s revmatoidnym artritom: predvaritel'nye rezul'taty. Nauchno-prakticheskaya revmatologiya. 2020; 58 (6): 673–7. Dostupno po ssylke: https://doi.org/10.47360/1995-4484-2020-673-677. Russian.
  25. Avdeeva AS, CHetina EV, Markova GA, Nasonov EL. Ekspressiya interferon-stimulirovannyh genov u pacientov s revmatoidnym artritom na fone anti-V-kletochnoj terapii (predvaritel'nye rezul'taty) Sovremennaya revmatologiya. 2021; 15 (5): 12–17. Russian.
  26. Avdeeva AS, Aleksankin AP, Chetina EV, Gorbunova YuN, Popkova TV, Markova GA, et al. Immunophenotypes of systemic lupus erythematosus — features of clinical and laboratory disorders. Doklady Biochemistry and Biophysics. 2025; 522 (1): 315–22.
  27. Panafidina TA, Popkova TV, Gorbunova YuN, Kondrateva LV, CHetina EV, Avdeeva AS, et al. Klinicheskoe znachenie interferonovogo statusa u pacientov s sistemnoj krasnoj volchankoj. Nauchno-prakticheskaya revmatologiya. 2025; 63 (1): 95–103. Russian.
  28. Aliev DB, Gajdukova IZ. Interferon-α i osobennosti sistemnoj krasnoj volchanki u pacientov s yuvenil'nym i vzroslym nachalom zabolevaniya. RMZH. 2022; 6: 3–6. Russian.
  29. Avdeeva AS, CHetina EV, Gorbunova YuN, Panafidina TA, Popkova TV. Interferonovyj «avtograf» u pacientov s sistemnoj krasnoj volchankoj – vzaimosvyaz' s laboratornymi i klinicheskimi pokazatelyami. Klinicheskaya laboratornaya diagnostika. 2025; 70 (8): 530–5. Russian.
  30. Brkic Z, van Bon L, Cossu M, van Helden-Meeuwsen CG, Vonk MC, Knaapen H, et al. The interferon type I signature is present in systemic sclerosis before overt fibrosis and might contribute to its pathogenesis through high BAFF gene expression and high collagen synthesis. Ann Rheum Dis. 2016; 75 (8): 1567–73. DOI: 10.1136/annrheumdis-2015-207392.
  31. Kakkar V, Assassi S, Allanore Y, et al. Type 1 interferon activation in systemic sclerosis: a biomarker, a target or the culprit. Curr Opin Rheumatol. 2022; 34 (6): 357–64. DOI: 10.1097/BOR.0000000000000907.
  32. Mutovina Z, Golovina O, Zhurina T, Zagrebneva A, Shagina I, Myshkin M, et al. Increased type 1 interferon signature in systemic scleroderma patients suggests unexplored therapeutic options. International Journal of Rheumatic Diseases: Volume 27, Issue S3 Special Issue: APLAR 26th Asia–Pacific League of Associations for Rheumatology Congress, 21–25 August 2024.
  33. Del Galdo F, Lescoat A, Conaghan PG, et al. EULAR recommendations for the treatment of SSc: 2023 update. Ann Rheum Dis. 2025; 84 (1): 29–40. DOI: 10.1136/ard-2024-226430.
  34. Khanna D, Denton CP, Assassi S, et al. DAISY study design and rationale: anifrolumab in SSc (phase 3). Clin Exp Rheumatol. 2024; 42 (8): 1635–44. DOI: 10.55563/clinexprheumatol/s8qcyu.
  35. van den Hoogen F, et al. 2013 classification criteria for systemic sclerosis. Arthritis Rheum. 2013; 65 (11): 2737–47. DOI: 10.1002/art.38098.
  36. Valentini G, et al. EScSG preliminary activity criteria: construct validity. Ann Rheum Dis. 2003; 62: 901–03. DOI: 10.1136/ard.62.9.901.
  37. Bong D, et al. Brief guide to RT-qPCR. Molecules and Cells. 2024; 47 (12): 100141. DOI: 10.1016/j.mocell.2024.100141.
  38. Chudakov DM, Turchaninova MA, Britanova OV, Shagina IA, Mutovina ZYu, avtory. Diagnosticheskaya test-sistema dlya ocenki funkcional'nogo sostoyaniya sistemy interferona pri autoimmunnyh vospalitel'nyh zabolevaniyah. Patent 2845958 ot 28.08.2025 g. Dostupno po ssylke: https://fips.ru/EGD/22f31495-c376-4c27-9260-553d619511a9. Russian.
  39. Schneider WM, Chevillotte MD, Rice CM. Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol. 2014; 32: 513–45. DOI: 10.1146/annurev-immunol-032713-120231.
  40. Lozhkov AA, Plotnikova MA, Egorova MA, Baranovskaya IL, Elpaeva EA, Klotchenko SA, et al. Simultaneous Detection of RIG-1, MDA5, and IFIT-1 Expression Is a Convenient Tool for Evaluation of the Interferon-Mediated Response. Viruses. 2022; 14 (10): 2090. DOI: 10.3390/v14102090.
  41. Egorova MA, Plotnikova MA, Lozhkov AA, Vlasov PK, Vasin AV, avtory. Mnogoparametricheskaya testovaya sistema dlya kolichestvennogo opredele niya mRNK genov RIG-1, IFIT-1, IFIH-1 metodom OT-PCR v real'nom vremeni. Patent RU2782428C1. 09.03.2023. Dostupno po ssylke: https://patents.google.com/patent/RU2782428C1/ru. Russian.
  42. Higgs BW, Liu Z, White B, Zhu W, White WI, Morehouse C, et al. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann Rheum Dis. 2011; 70 (11): 2029–36. DOI: 10.1136/ard.2011.150326.
  43. Morand EF, et al. Efficacy of anifrolumab across organ domains in SLE (TULIP-1/2). Lancet Rheumatol. 2022; 4 (4): e282–e292. DOI: 10.1016/S2665-9913(21)00317-9.